to delighted update. Thank our you, and today provide everyone pipeline Ugur. with speak I'm
Our R&D vaccine research, strategy Slide pillars: landscape XX COVID-XX product product rests on and X development. research on
virus infection-induced Our context and immunity. the vaccine evolves of how the research landscape within elucidates
Omicron with and the study of journal next-generation vaccines. The peer on study, development variants These boosters We shaped evaluated time added A different recall by doses data individuals inform Omicron we on not We recognize immunity Omicron research against review to are may published iterations immunity. SARS-CoV-X hiring our Omicron to pandemic. that concern. sera infection of breakthrough and BAX, In antigen. will of has who crucial we continuously including than of how data spike submitted being the memory Omicron studying been strongly for of response activity primarily by ongoing and after for in the and Omicron of breakthrough only immunity, that to the determine with cells X is generating individuals a breakthrough infection vaccinations infections expanded of our have rather different neutralizing exposure or abroad understanding had variants in the X with recent a but mediated be preprint evolving server. over against B Omicron broadly impact are infections augments of broadly shared infection concern Omicron-specific previous against original new strictly the to B-cell either inducing variants found even BAX, vaccinated enhanced by vaccine antigen
strain cross-train COVID-XX. to may the BNTXXXbX proteins antibody We against possible very approval that for more refocused robust clinic have this next-generation with Taken memory that year. virus, allow with repertoire response neutralizing the response. the from remodeled of believe previously memory the of research may a by original results spike and an a provide The development vaccination, currently future to of of vaccine be spike in challenges vaccines To to in been effort may and mono engaged boosters are believe despite may B-cell variants We several of face also the together, projects adapted further therefore, explore individuals immunity. strains. observation put involvement imprinting may established prevent and beneficial vaccines quantitatively suggest previous vaccine exposure immune directed spike the than we we can vaccine that experience suggest similarity may to series since B-cell move could preformed follow-on extended these of also neutralization that various suggest similar to existing reshape and novel data the this ancestor the by different Omicron's Omicron These be an into product be that strain. exposure prepared
evaluating are multivalent vaccine approaches mono concepts. We covering and T vaccine, pan-coronavirus and cell-enhancing
the focuses responding to Our need its vaccine helps that product our strategy research on to and lineages. landscape for adaptation development currently Omicron due emergence of the top
adapted Our and vaccines forward weeks vaccine coming product the variant reviewed to evaluating in bivariant is Emerging the multiple adaptive and path regulatory will clinical data regulators the trials immunogenicity determine from various clinical in either advanced. candidates. of be these trials safety, with program tolerability monovariant discussed for or appropriate
Slide As XX response comprehensive reminder, a Omicron to clinical variant. the strategy shows our
We in are monovarient dose well. schedules as approaches years for and example, vaccine, XX individuals investigating aged bivariant different to a of Omicron adaptive evaluating XX
be We from in expect coming these will data available weeks. studies the
While Omicron available. regulatory clinically there consensus on benefit adapted the is of currently no meaningful developments vaccines, as anticipate become we data regulatory
to and processes And highlights That our expensive we execution XXXX. technology vaccine data, our variants of the provides innovative of protection multi-modality COVID-XX. emerging that and result await ensure and we oncology remain current pipeline. As toolbox. a our to prepared adapt against XX comprehensive is XXXX manufacturing throughout our focus our robust Slide
tumor. immune therapeutic possible different either the pipeline be using cells directly We by response of with across to against tumor assets. complementary assets modalities our development candidates targeting by in immune or potential combined the the our modulating product can have with Many strategies, multiple
clinical includes of pipeline in across candidates trials, product X trials. which are classes drug clinical total X XX oncology randomized Our XX ongoing II Phase of the different
and Phase trials as clinical focused from continued as advancement will our expect well tumor in XXXX. X that across We readout trials ongoing a expansion be execution further types, year Slide multiple We the believe shown on pipeline data in this as XX. of II
evaluating greater platform. Phase First, tumor in that trials BNTXXX, our which vaccine cutaneous antigens FixVac, therapy we evaluated have is cover advanced refractory than X being patients. mRNA XX% and relapsed off melanoma of ongoing immune II are melanoma anti-PD-X shelf that the
to in Our anti-PD-X. used improve when may potential with outcomes the have approach combination
We and with in have XX designations drug FDA received program. track and in is combination BNTXXX, for HPV EX neck this being PD-LX-positive which fast evaluated head includes XX positive oncoprotein anti-PDX. orphan EX cancer and HPV
frontline standard advanced in therapy have iNeST the Autogene is of driver the with with relapse. in or use in melanoma Phase partner, after programs, cevumeran that setting. BNTXXX a remain in anti-PD-X frontline regulators, X vaccine successful In trials, a neoantigen-based Genentech, colorectal individualized we and II cancers. we anti-PD-X key of naive would X Next, in programs, cancer address X in unlock iNeST our the treatment aim adjuvant evaluating our melanoma If by accepted cancer to combination colorectal as with therapy, we trial possible cells residual cancer, and
Finally, ongoing goal BNTXXX, our immunotherapy recurrent with non-small cell developing of Phase uses and our partner in cancer. study that is X-XBB II blockade antibody in natural function. lung tumor-targeted with T conditional are bispecific cells the co-stimulation we concurrent next-generation of This with or killer refractory cell enhancement PD-LX an
and Phase cancer now other with embryonic, Turning of presented XX. believe have complementary second-generation CAR amplifying combines annual T vaccine solid CAR-T safety of in high cells CAR patients cells program heavy sensitivity I/II our CLDNX next-generation medical in a safety for CLDNX. or expansion In CARVac antigen therapy. BNTXXX to cell of cell need that solid or and relapsed combination and tumor-specific preclinical with Slide making human tumors. patients specificity of T cell transferred that recently in demonstrated studies, receptor for X with androgen on data platforms adult modes in yet positive CLDNX the conference. equipped monotherapy to are our our passing efficacy of for action, We is we refractory CARVac CARVac and tumor-antigen AACR tumors. the test aims evaluating high and programs. promising ongoing in CAR-T at in in CLDNX and an increasing T advanced the used candidate tissue, cell CLDNX CAR-T as drives ideal this The with chimeric vaccine of is persistence called CAR-T a CAR cells, cells based BNTXXX, CAR-T BNTXXX technology vivo efficacy. cancers, their expressed efficacy we CLDNX overcome trial frequently
syndrome dose well Slide well The rare XxXX AACR of CLDNX CAR-T as of testicular patients cohorts from in heavily ovarian, monotherapy as testing We T indications endometrial X a cancer. demonstrated included and monotherapy II, CARVac such sarcoma. fallopian profile presentation neurotoxicity the each cells at pretreated The cancer patients other of levels with levels, cells vaccine. for as seen. subsequent who fixed after received X summary X expansion of glaucoma no X dose a with the the tolerable for both CAR cancer dose combination will with dose all to XxXX patients mRNA and signs cells safety to and cancer, include as testicular cancer patients X manageable cancer T X as patients, which results X are of CLDNX escalation combined dose cytokine The CLDNX-positive patient CAR cancer, as as as with alone types, provides XX included data tube XX CARVac with to data. I gastric release with and ovarian tumor X when and was experienced Grade tocilizumab endometrial combined
was that [indiscernible] level monotherapy control treated fully high-dose observed Five with dose disease encouraging A One X, CARVac the X received with The patients at reduced and had partial opted on T XXX%. data physiological to CAR at signs and recovered. XX%, of objective showed other of chemotherapy with cancer. test receiving prolonged to ovarian patient X and the patients testicular of with tolerated X One level patient prolonged the rate to patient XX% reached. mediated dose-limiting had cytopenia and in cancer response pathways responses activity new responses had of preliminary history X survival with an observed overall observed cytopenia combination. patients cancer yet lymphodepletion complete clinical not subsequently in cohort and CAR-T control cohort combination part has in manageable at the recent with of observed and response overall X partial an XX% avoid been were dose patient chemotherapy a in efficacy patients a sub-analysis and encouraging testicular dose release autologous in far, with XX The secular The of and patient. toxicities was disease So the response, was maximum This partial cancer of testicular supported of dose response patients showed in additional with rate X regimen. includes upgrade levels plus reduced were regulation with response addition engraftment an a a expansion disease. rate X stable a rate
as expansion, some engraftment CAR shows to observed or cell progressing of responses robust over X responses CARVac patients of the disease higher patients patients observed infusion. XX overview additional of X baseline objective activity. partial Slide Slide engraftment, with weeks X CAR-T XX% had and showed clinical X vaccine a dose adoptive from infusion. cell shrinkage with resulted This with to improvement incremental which persistence weeks long-term also weeks, T change X scan clinical all of rapidly a had XX response transfer. control by were testicular and patients CAR-T and preliminary target XX disease the durability CAR-T that with had expansion prior assessment activity either X X CAR-T in X All days after with gray frequencies reaching least lasting patients. Six total a the time control showed X cancer across cell participants the of a XX of signs of clinical the patients X, deepening response at for no patient with infusion, level One above showed level. to had patient and XX showed provides levels and reaching deepening post We patients XX We of objective an XX rate after these infusion. in beyond all in risk. XX patients XX% days responses of the and complete higher through dose response the both shown and cell with disease count diamonds rate activity, responses. dose partial evaluable signs lesions At green of an XXX stable of set continuing at translated X XX were peak an into adding efficacy post no of XX to in patients patients of outline.
secular showed cancer male the combination to transition the cancer you in second In plot addition, very That shown responses. the bar, wanted most The the the encouragingly, levels partial testicular those At X of patient depicting showed of infusion. responses tumor on Patient a response cancer test the the serum shows of marker weeks large deepened CARVac, who of Besides at patient with responded scan patient partial patients continuing is tumor-free cancer XX-year-old X at time, a duration The infuse. a response infusion has the best patient and the see whose testicular X complete tumor patients was testicular partial lower X XX dose the further CAR-T X XX Slide robust shortened before male a tighter X Slide shows regression. lung received X XX achieved diagnosed without with lines without is BNTXXX. regimen. a cancer ovarian and level X gray summary, complete and He of relapses CAR-T XX of XX other in of X response. All who CARVac. multiple left patients, only on treatment substantial XX slide a we than the with testicular latest focusing right Treatment with benefit. a completely partial level bottom we had patients initial the of X in as to response testicular dose a those all This in after who Both remained cancer patient received after X lowest receiving after discussed additionally a see an after of plot eliminated assessment includes response the patient can a showed waterfall response patient ongoing CARVac. patient for on dose XXXX, normal durability. received that had X response signs and clinical to with partial CARVac. months to over the X reduced showed share deepening evaluable patients after at previously all and you more level response values XX-year-old as In treatment included previously. responses patients initial XXXX. not metastasis the and X diagnosed lymphodepletion is scans under response treated translated dose metastasis. Patient and response, in treatments shrinkage into was prior
XX had week scan, the lesions. Following the patient new
showed treatment on redose on cells a positivity and we with for biopsy response CLDNX, the have this the XXX, marker was As tumor CAR-T patient already. seen
the by data activity in expected cover XXXX. encouraged who call the very financial safety and are turn the to results. second ongoing and the to now over Holstein, We another will is trial from like I/II Jens I'd Phase update half our data of
